Cite
S1605 HORIZON (OP-106): UPDATED EFFICACY AND SAFETY OF MELFLUFEN IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO DARATUMUMAB (DARA) AND/OR POMALIDOMIDE (POM)
MLA
M.V. Mateos, et al. “S1605 Horizon (Op-106): Updated Efficacy and Safety of Melflufen in Relapsed/Refractory Multiple Myeloma (Rrmm) Refractory to Daratumumab (Dara) And/Or Pomalidomide (Pom).” HemaSphere, vol. 3, June 2019, p. 739. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........095eff044494d21f18b845c120d724ea&authtype=sso&custid=ns315887.
APA
M.V. Mateos, A. Paner, J. Harran, A. Alegre, J. Bladé, M. Cavo, C. Maisel, A. Oriol, A. Larocca, P. G. Richardson, Jeffrey A. Zonder, X. Leleu, Noemi Puig, H. Hassoun, H. Zubair, J. Harmenberg, Amitabha Mazumder, M. Norkin, S. Thuresson, & Paula Rodriguez Otero. (2019). S1605 Horizon (Op-106): Updated Efficacy and Safety of Melflufen in Relapsed/Refractory Multiple Myeloma (Rrmm) Refractory to Daratumumab (Dara) And/Or Pomalidomide (Pom). HemaSphere, 3, 739.
Chicago
M.V. Mateos, A. Paner, J. Harran, A. Alegre, J. Bladé, M. Cavo, C. Maisel, et al. 2019. “S1605 Horizon (Op-106): Updated Efficacy and Safety of Melflufen in Relapsed/Refractory Multiple Myeloma (Rrmm) Refractory to Daratumumab (Dara) And/Or Pomalidomide (Pom).” HemaSphere 3 (June): 739. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........095eff044494d21f18b845c120d724ea&authtype=sso&custid=ns315887.